论文部分内容阅读
目的探讨白三烯受体拮抗剂孟鲁司特治疗儿童哮喘的临床疗效。方法将130例6~14岁的中度哮喘儿童分为口服孟鲁司特5mg/d、吸入激素(布地奈德200μg/d、氟替卡松250μg)、孟鲁司特5mg/d联合激素(布地奈德200或100μg)共5组,持续治疗12周。于治疗开始和第12周进行临床评估和肺功能检查。结果患儿治疗后临床评分和一秒钟最大呼气量及用力呼气峰流速明显改善。口服孟鲁司特联合吸入激素组疗效优于单服孟鲁司特或吸入激素组,但各组间临床疗效比较差异无显著性(P>0.05)。结论孟鲁司特能有效抑制气道收缩,改善肺功能,控制哮喘的临床症状;与皮质激素合用,哮喘症状改善明显,且可减少激素的用量。
Objective To investigate the clinical efficacy of leukotriene receptor antagonist montelukast in children with asthma. Methods 130 children aged 6-14 years with moderate asthma were divided into montelukast oral 5mg / d, inhaled hormones (budesonide 200μg / d, fluticasone 250μg), montelukast 5mg / d combined with budesonide Germany 200 or 100μg) for a total of 5 groups, for 12 weeks. At the beginning of treatment and at week 12, clinical evaluation and pulmonary function tests were performed. Results After treatment, the clinical score and maximum expiratory volume in one second and forced expiratory peak flow rate were significantly improved. Oral montelukast combined with inhaled hormone group than montelukast or inhaled hormone group, but no significant difference between the clinical efficacy (P> 0.05). Conclusion Montelukast can effectively inhibit airway contractions, improve lung function and control the clinical symptoms of asthma. Combined with corticosteroids, asthma symptoms can be obviously improved, and the amount of hormones can be reduced.